XML 57 R28.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Significant Accounting Policies - Additional Information (Details) | 1 Months Ended | 12 Months Ended
--- | --- | ---
Jul. 31, 2017 USD ($) | Dec. 31, 2017 USD ($) LicenseAgreement Segment | Dec. 31, 2016 USD ($)
Summary Of Significant Accounting Policy [Line Items] |  |  |
Change in value of short-term investments |  | $ 0 |
Impairment loss for long-lived assets |  | $ 0 | $ 0
Number of deliverable license agreements | LicenseAgreement |  | 2 |
License component, description |  | The license component has standalone value (and therefore is accounted for separately from the supply services) since Allergan can use the license for its intended purposes without the Company’s supply services. The four conditions of ASC 605 were met as of December 31, 2017 and 2016: (1) persuasive evidence of an arrangement exists since the Company and Allergan engaged with a binding agreement; (2) delivery has occurred or services have been rendered since all documents and data Allergan has requested relating to the Company’s know-how were provided before December 31, 2016 and Allergan can use the license for its intended purposes without the supply services (except for immaterial support services); (3) the fee is fixed or determinable, as indicated in the license agreement; and (4) collectability is reasonably assured. |
Upfront fee allocated to license component |  | $ 17,500,000 |
Increase (decrease) in research and development expenses |  |  | 175,000
Accrued provision for uncertain tax positions |  | $ 0 | 0
Number of operating segments | Segment |  | 1 |
General and Administrative Expenses |  |  |
Summary Of Significant Accounting Policy [Line Items] |  |  |
IPO costs |  | $ 0 | 1,700,000
Allergan |  |  |
Summary Of Significant Accounting Policy [Line Items] |  |  |
Consideration received for license and future supply services |  |  | 17,500,000
Milestone payment for licensing agreement | $ 7,500,000 |  |
Increase (decrease) in research and development expenses |  |  | $ (126,000)

X
- Definition Consideration fee received for license and future supply services. + References No definition available. + Details
Name: | urgn_ConsiderationFeeReceivedForLicenseAndFutureSupplyServices
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Description of license agreement components. + References No definition available. + Details
Name: | urgn_DescriptionOfLicenseAgreementComponents
Namespace Prefix: | urgn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (decrease) in research and development expenses. + References No definition available. + Details
Name: | urgn_IncreaseDecreaseInResearchAndDevelopmentExpense
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Initial public offering cost. + References No definition available. + Details
Name: | urgn_InitialPublicOfferingCost
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payment for licensing agreement. + References No definition available. + Details
Name: | urgn_MilestonePaymentForLicensingAgreement
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of deliverable license agreements. + References No definition available. + Details
Name: | urgn_NumberOfDeliverableLicenseAgreements
Namespace Prefix: | urgn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of significant accounting policy. + References No definition available. + Details
Name: | urgn_SummaryOfSignificantAccountingPolicyLineItems
Namespace Prefix: | urgn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront fee allocated to license component + References No definition available. + Details
Name: | urgn_UpfrontFeeAllocatedToLicenseComponent
Namespace Prefix: | urgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 958 -SubTopic 225 -Section 45 -Paragraph 11 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=84241808&loc=d3e92212-112881 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=68055307&loc=d3e2420-110228 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=84176398&loc=d3e2921-110230 + Details
Name: | us-gaap_ImpairmentOfLongLivedAssetsHeldForUse
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + References No definition available. + Details
Name: | us-gaap_NumberOfOperatingSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585 + Details
Name: | us-gaap_UnrealizedGainLossOnInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of unrecognized tax benefits. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 50 -Paragraph 15A -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319 + Details
Name: | us-gaap_UnrecognizedTaxBenefits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=urgn_AllerganPharmaceuticalsInternationalLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |